Zacks Investment Research upgraded shares of ArQule, Inc. (NASDAQ:ARQL) from a hold rating to a buy rating in a research report sent to investors on Friday morning. Zacks Investment Research currently has $1.25 price objective on the biotechnology company’s stock.

According to Zacks, “ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule’s lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company’s lead ACT program, based on the E2F-1 pathway, is partnered with Roche. “

Separately, ValuEngine downgraded ArQule from a sell rating to a strong sell rating in a report on Friday, September 1st.

Shares of ArQule (NASDAQ ARQL) traded up 5.31% during midday trading on Friday, hitting $1.19. The stock had a trading volume of 422,221 shares. The company’s market cap is $84.69 million. ArQule has a one year low of $0.92 and a one year high of $1.82. The stock has a 50 day moving average of $1.09 and a 200-day moving average of $1.13.

ArQule (NASDAQ:ARQL) last issued its quarterly earnings results on Friday, August 4th. The biotechnology company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. ArQule had a negative return on equity of 135.68% and a negative net margin of 482.44%. During the same period in the prior year, the company earned ($0.07) earnings per share. Analysts forecast that ArQule will post ($0.43) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/16/arqule-inc-arql-upgraded-by-zacks-investment-research-to-buy.html.

An institutional investor recently raised its position in ArQule stock. Northern Trust Corp lifted its stake in shares of ArQule, Inc. (NASDAQ:ARQL) by 0.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 154,513 shares of the biotechnology company’s stock after purchasing an additional 1,385 shares during the quarter. Northern Trust Corp owned about 0.22% of ArQule worth $192,000 as of its most recent filing with the Securities and Exchange Commission. 60.95% of the stock is owned by institutional investors.

ArQule Company Profile

ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.

Receive News & Ratings for ArQule Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule Inc. and related companies with MarketBeat.com's FREE daily email newsletter.